Government orders 44.75 million doses of anthrax vaccine from Emergent BioSolutions

Emergent BioSolutions, Inc., recently announced that it has received a contract to supply the U.S. government with 44.75 million doses of its anthrax vaccine, BioThrax, over a period of five years.

"Companies like Emergent BioSolutions are leading the way forward as we work to reinvent Michigan," Michigan Governor Rick Snyder said.  "When these kinds of jobs come to an area, they create their own gravity and draw in more highly educated workers. As Emergent is a critical and long standing employer in the Lansing region, this is great news for both the local economy and the entire state."

In past contracts, Emergent BioSolutions, Inc., has delivered 55 million doses of BioThrax, the only vaccine licensed by the U.S. Food and Drug and Drug Administration, according to the Baltimore Sun.

“Emergent is proud to be able to contribute to the U.S. government’s program of protecting the nation from the threat of anthrax,” Fuad El-Hibri, the chairman and chief executive officer of Emergent BioSolutions, Inc., said.

Initial deliveries of the vaccine under this contract are expected to begin in 2011, with 8.5 million doses prepared in the first year. The company will retain the right to modify the timing of the deliveries over the five year period depending on factors such as manufacturing yield.

“This five year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs,” El-Hibri said. “In coming to agreement, Emergent and the Centers for Disease Control and Prevention worked diligently to establish business terms that incorporate substantial price concessions.”